HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (54) Citing Articles via Google Scholar Google Scholar Articles by Bonen, A. Articles by Glatz, J. F. C. Search for Related Content PubMed PubMed Citation Articles by Bonen, A. Articles by Glatz, J. F. C.

Mechanisms and Regulation of Protein-Mediated Cellular Fatty Acid Uptake: Molecular, Biochemical, and Physiological Evidence

Arend Bonen¹, Adrian Chabowski², Joost J. F. P Luiken³ and Jan F. C. Glatz³

¹ Department of Human Health and Nutritional Sciences, University of Guelph, Guelph, Ontario, Canada, abonen{at}uoguelph.ca
² Department of Physiology, Medical University of Bialystok, Bialystok, Poland, and
³ Department of Molecular Genetics, Maastricht University, Maastricht, The Netherlands.

	Introduction

Top Introduction Evidence that Fatty Acids... Critique of Determining Fatty... Defining the Process of... Molecular Evidence for Membrane... Studies In Vitro Studies In Vivo Why so Many Membrane... Do Fatty Acid Transporters... Chronic Regulation of Fatty... Acute Regulation of Fatty... Fatty Acid Transport and... Unsuspected Role of FAT/CD36... Summary References

 

Arend Bonen Department of Human Health and Nutritional Sciences, University of Guelph, Guelph, Ontario, Canada abonen{at}uoguelph.ca

Adrian Chabowski Department of Physiology, Medical University of Bialystok, Bialystok, Poland

Joost J. F. P Luiken Department of Molecular Genetics, Maastricht University, Maastricht, The Netherlands

Jan F. C. Glatz Department of Molecular Genetics, Maastricht University, Maastricht, The Netherlands

Fatty acids serve as substrates for diverse cellular processes, including membrane biosynthesis, protein modification, regulation of transcription, intracellular signaling, and energy provision for tissues such as liver, heart, and skeletal muscle. Although these processes are highly regulated, it has long been thought that entry of long-chain fatty acids into parenchymal cells occurs in an unregulated manner by diffusion (57–60). However, from a physiological perspective, it may be speculated that it would be highly desirable to regulate the entry of fatty acids into the cell, given their important roles in many key cellular processes. In addition, since fatty acids may exert harmful effects, related to their detergent-like action (114, 122), such detrimental effects could be better controlled if fatty acid entry into the cell was regulated.

In recent years, there has been considerable debate as to whether fatty acid is transported into cells or diffuses rapidly into the cell. It now appears that this debate is less strident, as it has been acknowledged recently that evidence supporting passive diffusion as the main mechanism for fatty acid uptake is apparently in error, since "previous reports for rapid flip-flop were based on an incorrect interpretation of the measurements" (79), Because of this (79) and other experiments (78), it has been concluded that "the lipid bilayer portion of biological membranes may present a significant barrier to transport of FFA across cell membranes" (36) and that "flip-flop is the rate limiting step for FFA transport across lipid vesicles" (78). Furthermore, "this implies that at least certain biological membranes may require protein-mediated transporters to catalyze the flip-flop step" (78).

Since we (13, 27–29, 73, 97, 98, 100) and others (32, 45, 54) have previously provided considerable support for the protein-mediated entry of long-chain fatty acids into the cell, especially in metabolically important tissues such as heart and skeletal muscle, we concur with these recent conclusions (36, 78, 79) that (membrane-associated) proteins are involved in cellular fatty acid uptake. Indeed, very solid evidence, based on physiological, biochemical, molecular, and genetic studies, supports the idea that fatty acid entry into many tissues occurs via a protein-mediated mechanism that is highly regulatable both acutely (within minutes) and chronically (hours to weeks). We (13, 27–29, 73, 97, 98, 100) and others (32, 45, 54) have identified in heart and skeletal muscle some of the proteins that facilitate the movement of fatty acids across the plasma membrane, their regulation by physiological signals, as well as the signaling pathways involved. In addition, we (18, 96) have also found that these proteins may mediate, in part, the development of fatty acid-induced insulin resistance.

We agree with Kampf and Kleinfeld (80) that the exact mechanics of how fatty acids are transferred across the plasma membrane are not known, whether in adipose tissue, heart, or skeletal muscle. We do not dismiss the idea that fatty acids can also diffuse into the cell. However, under physiological conditions, diffusion of fatty acids appears to be quantitatively less important (40), as has also been shown for lactate (105, 106) and glucose (85). It would not be completely surprising if the proteins involved in transporting fatty acids and/or their regulation would differ in adipocytes and muscle tissue (heart and skeletal muscle) given the very different metabolic roles and physiological functions of these tissues. The purpose of the present paper is to examine 1) the key evidence in support of a highly regulated, protein-mediated system that is involved in delivering fatty acids across the plasma membrane and 2) how this transport process may contribute to regulating fatty acid metabolism. The emphases throughout is on studies in mammalian tissues, primarily heart and skeletal muscle, in which fatty acid transport appears to be a key component in regulating fatty acid metabolism.

	Evidence that Fatty Acids are Taken Up via Protein-Mediated System into Giant Sarcolemmal Vesicles

Top Introduction Evidence that Fatty Acids... Critique of Determining Fatty... Defining the Process of... Molecular Evidence for Membrane... Studies In Vitro Studies In Vivo Why so Many Membrane... Do Fatty Acid Transporters... Chronic Regulation of Fatty... Acute Regulation of Fatty... Fatty Acid Transport and... Unsuspected Role of FAT/CD36... Summary References

 
For some time, determinations of fatty acid movement across the plasma membrane had occurred in either in vitro (reviewed in the accompanying paper Ref. 80) or in more biological preparations in which entry of fatty acids into the cell was not clearly distinguishable from the concurrent fatty acid metabolism, although the corrections introduced provided a reasonable approximation of fatty acid transport across the plasma membrane (2, 5, 6). Nevertheless, these different approaches led to conflicting results. In an attempt to solve the conundrum and realizing that both of these foregoing approaches may limit proper conclusions concerning the fatty acid uptake and its regulation, we set out 1) to use a vesicle preparation in which only the rates of fatty acid movement across the plasma membrane can be examined (i.e., in the absence of their metabolism) and 2) to derive such vesicles from metabolically important mammalian tissues. Therefore, we began to use the giant vesicles prepared from skeletal muscle (14) and the heart (102).

We have detailed previously how these vesicles are prepared and how fatty uptake measurements are made (14, 88, 102). Briefly, giant vesicles can be prepared from most tissues by simply removing the tissue from the animals and scissoring these tissues into narrow strips (1–3 mm). Thereafter, the strips are incubated (1 h, 34°C) in 140 mM KCl/10 mM MOPS (pH 7.4) containing a protease inhibitor (aprotinin) and an appropriate collagenase for the tissue in question. Thereafter, the vesicles are recovered from the incubating medium after centrifugation, i.e., at the interface of a 3 ml, 4% Nycodenz layer, and a 1 ml KCl/MOPS upper layer. Recovered vesicles are then resuspended in KCl/MOPS. At this point, vesicles can be maintained for some time at room temperature or overnight at 4°C, and possibly even longer. For transport studies, protein concentrations of the vesicles are normally determined immediately. Thereafter, protein (50 µg) is added to small tubes. Radiolabeled palmitate and unlabeled palmitate (previously complexed to fat-free bovine serum albumin), as well as radiolabeled mannitol, are then added (40-µl volume) to the vesicles and quickly mixed. Typically, the reaction proceeds for 15 s. At that point, an ice-cold HgCl₂ stop solution is added. Thereafter, vesicles are pelleted, the supernatant fraction is removed, and the radioactivity is determined in the pellet cut from the tip of the tube. Standard calculations are performed to determine the molar quantity of palmitate taken up in 15 s.

Key features of this giant vesicle preparation include the following: 1) giant sarcolemmal vesicles have a large volume (10- to 15-µm diameter), which permits measurement of fatty acid entry over a 2- to 30-s range, during which time the rate of palmitate uptake remains linear (i.e., backflux is not occurring), while the concentration of extra-vesicular palmitate in the assay is not altered; 2) giant sarcolemmal vesicles are oriented 100% right-side out, which may be important depending on how fatty acids cross the plasma membrane; and 3) in the lumen of giant sarcolemmal vesicles there are excess quantities of the 15-kDa cytoplasmic fatty acid binding protein (FABPc), which is required to act as a sink for fatty acids that have crossed the plasma membrane (14, 86, 88). Absence of FABPc in the lumen of giant vesicles compromises the uptake of fatty acids (99), thereby demonstrating the critical role of this protein in the desorption of fatty acids from the plasma membrane.

Studies of the rates of fatty acid entry into heart- and skeletal muscle-derived giant vesicles have provided convincing evidence in support of the involvement of a protein-mediated system. In these giant vesicles, the rate of entry of long-chain fatty acids is saturable (FIGURE 6A), suggesting the presence of a limiting factor. Pretreating giant sarcolemmal vesicles with protein modifying agents (trypsin and phloretin), as well as with a reactive oleate ester [sulfo-N-succinimidy-loleate (SSO)] and antisera to a putative fatty acid transporter, inhibited fatty acid entry into the vesicles by 30–50% (14, 102) (FIGURE 6B). In addition, palmitate entry into giant vesicles was displaced by another long-chain fatty acid (oleate) but not by a short-chain fatty acid (octanoate) or by glucose (14, 102), illustrating that the transport system is specific for long-chain fatty acids (FIGURE 6B). Finally, the palmitate that was transported into giant sarcolemmal vesicles was fully recovered in the lumen of these vesicles and was not further metabolized (FIGURE 6C). Collectively, these studies demonstrated that long-chain fatty acids traverse the plasma membrane in heart and skeletal muscle largely via a protein-mediated system.

View larger version (42K): [in this window] [in a new window]   FIGURE 6. Characterization of fatty acid transport into giant sarcolemmal vesicles obtained from heart and skeletal muscle A: kinetics of palmitate transport into giant sarcolemmal vesicles from heart and red and white skeletal muscle. B: inhibition of palmitate transport into giant sarcolemmal vesicles, demonstrating the presence of a protein-mediated mechanism as well as specificity for long-chain fatty acids. C: confirmation that all of the palmitate that is transported into giant sarcolemmal vesicles is recovered in the cytosol of the vesicles (i.e., not associated with the plasma membrane) and that all of the lipid in the cytosol is recovered as fatty acid only, as determined by thin-layer chromatography (i.e., no metabolism of palmiate transported into the giant sarcolemmal vesicles is observed). D: correlation between the fatty acid transporter FAT/CD36 located on the plasma membrane of giant sarcolemmal vesicles and the rate of palmitate transport into giant sarcolemmal vesicles. Data are redrawn from studies by Bonen et al. (14) and Luiken, Turcotte, and Bonen (102).

Clearly, the giant sarcolemmal vesicles used in our laboratories offer many advantages, including the ability to conduct studies using metabolically important studies from rodents as well as humans (see below). There are, however, also some limitations. First, considerable quantities of fresh tissue are required to generate sufficient vesicles for transport studies (preferably 0.5–1 g). Second, it is possible that preparation of the vesicles isolates specific subplasmalemmal domains, as we have observed that vesicles generated from heart, muscle, liver, and adipocytes are more or less similar in size (88, 96). Another concern is that giant vesicles are only derived from the plasma membrane, whereas T-tubules are completely excluded. This may be important, since substrate transport proteins are present in T-tubules [GLUT4 (92) and MCT1 and 4 (17)], and we have also found FAT/CD36 and FABPpm in this location (unpublished observations). It is known that GLUT4 can be induced to translocate to the T-tubules (90, 92), and these invaginations represent an efficient means of distributing substrates into the muscle cell’s interior. Extensive use of giant vesicles has therefore precluded any assessment of the role of T-tubules in fatty acid transport into muscle tissues.

	Critique of Determining Fatty Acid Transport

Top Introduction Evidence that Fatty Acids... Critique of Determining Fatty... Defining the Process of... Molecular Evidence for Membrane... Studies In Vitro Studies In Vivo Why so Many Membrane... Do Fatty Acid Transporters... Chronic Regulation of Fatty... Acute Regulation of Fatty... Fatty Acid Transport and... Unsuspected Role of FAT/CD36... Summary References

 
In the accompanying paper (80), it is noted that the uncertainty about plasma membrane fatty acid transport arises because uptake measurements do not clearly distinguish the actual transport step. Certainly, we (13, 27–29, 73, 97, 98, 100) and others (32, 45, 54) have focused on establishing whether there is a transport-like process of transferring fatty acids across the plasma membrane and determining which proteins are involved in this process. We concur that these approaches shed no light on the actual transport steps. However, the converse also appears to be the case: namely that exclusive focus on the specific transport steps in the membrane has limited an appreciation (57–60) for a considerable body of work supporting the evidence for a fatty acid transport-like process, particularly in metabolically important tissues.

Concerns that uptake measurements are not sensitive to unbound cytosolic fatty acids (80) are likely not a serious problem in giant vesicles. Cytosolic fatty acid content in skeletal muscle is extraordinary low (82, 141), and fatty uptake by giant vesicles proceeds in a linear fashion for at least 30 s (14), indicating that uptake is not being impaired by intravesicular fatty acid accumulation. Moreover, within these giant vesicles, there is excess FABPc that acts as a fatty acid sink (14). In addition, all the fatty acids that have been transported into the vesicles are recovered as fatty acids from the lumen (cytosol) of the giant vesicles (14) (see FIGURE 6C).

Other critiques (80) are that determination of saturated fatty acid uptake relies on the subtraction of a linear component, assumed to be diffusion, and there may be errors in calculating unbound fatty acid concentrations. However, inhibition of plasmalemmal fatty acid transporters (14, 102, 139) or ablation of a fatty acid transporter markedly reduces the rate of adipocyte fatty acid transport (45). In addition, in these FAT/CD36-null mice, only a linear (non-protein mediated) rate of fatty acid uptake is observed in adipocytes (45). Collectively, these experimental observations suggest strongly that determination of saturated fatty acid transport as currently done is not an artifact.

The final critique (80) states that uptake of exogenous fatty acids must not perturb cell-associated fatty acids already present, and hence their efflux must be prevented with specific reagents, something that was not achieved in 3T3F442A adipocytes (79). This critique would seem to relate specifically to adipocytes, since these may well contain a considerable amount of intracellular fatty acids. As noted above, in giant vesicles derived from heart and muscle, the intracellular fatty acids are likely very low, and the linearity of initial rates of exogenous fatty acid uptake indicates little or no efflux is occurring. Moreover, we have had no difficulty in blocking fatty acid uptake into giant vesicles. Apparently, the difficulty in inhibiting fatty acid uptake in adipocytes (80) appears to be unique to this model system and does not apply to our giant vesicle preparation. Thus concerns about methodological inadequacies in fatty acid transport determinations appear to be far less problematical in muscle- and heart-derived giant vesicles as opposed to adipocytes, which appear to provide the frame of reference for some of the methodological critique (80).

	Defining the Process of Plasmalemmal Fatty Acid Transport

Top Introduction Evidence that Fatty Acids... Critique of Determining Fatty... Defining the Process of... Molecular Evidence for Membrane... Studies In Vitro Studies In Vivo Why so Many Membrane... Do Fatty Acid Transporters... Chronic Regulation of Fatty... Acute Regulation of Fatty... Fatty Acid Transport and... Unsuspected Role of FAT/CD36... Summary References

 
We have opted to refer to the process of protein-mediated fatty acid movement across the plasma membrane as fatty acid transport. We recognize that this transport process may differ from that of other substrates, such as glucose and lactate. Moreover, the molecular mechanisms of the transmembrane translocation of fatty acids remain elusive, because the molecular structure and membrane topology of the various fatty acid transporters are not fully known. Importantly, the molecular mechanism of transmembrane translocation of fatty acids may include a flip-flop of the fatty acid from one leaflet to another (as explained below) (51). These caveats, however, should not impede usage of the term fatty acid transport, especially since the regulation of protein-mediated long chain fatty acid movement across the plasma membrane is very similar to that of glucose transport [see detailed review by Luiken et al. (93) concerning these similarities].

	Molecular Evidence for Membrane Fatty Acid Transporters

Top Introduction Evidence that Fatty Acids... Critique of Determining Fatty... Defining the Process of... Molecular Evidence for Membrane... Studies In Vitro Studies In Vivo Why so Many Membrane... Do Fatty Acid Transporters... Chronic Regulation of Fatty... Acute Regulation of Fatty... Fatty Acid Transport and... Unsuspected Role of FAT/CD36... Summary References

 
Different groups have identified integral and peripheral membrane proteins that appeared to be involved in the transport of fatty acids into parenchymal cells. These proteins are commonly referred to as fatty acid transporters, despite the remaining uncertainty as to the exact mechanism by which any one of these proteins participates in the transport process. The known fatty acid transport proteins include 1) a family of ~70-kDa fatty acid transport proteins (FATP1–6) (50, 70, 119), 2) the 40-kDa plasma membrane associated fatty acid binding protein (FABPpm) (121, 133), and 3) the heavily glycosylated 88-kDa fatty acid translocase, also known as CD36 (FAT/CD36) (1).

The murine FATPs appear to be expressed in somewhat of a tissue-specific manner (50, 70, 91), and species specificity in expression patterns also appears to be present (91). In contrast, FAT/CD36 and FABPpm (10) are ubiquitously expressed in almost all rodent tissues examined. In humans, fatty acid transporters are expressed in skeletal muscle (FATP1 and 4, FABPpm, and FAT/CD36) (16, 24, 25), heart (FAT/CD36) (69), and adipose tissue (FATP1 and 4, FAT/CD36, FABPpm) (8, 22, 48). Support for facilitating long-chain fatty acid transport by many of these differing transporters has been obtained from genetic studies in cell lines and animals, as well as from physiological studies in mammalian tissues.

	Studies In Vitro

Top Introduction Evidence that Fatty Acids... Critique of Determining Fatty... Defining the Process of... Molecular Evidence for Membrane... Studies In Vitro Studies In Vivo Why so Many Membrane... Do Fatty Acid Transporters... Chronic Regulation of Fatty... Acute Regulation of Fatty... Fatty Acid Transport and... Unsuspected Role of FAT/CD36... Summary References

 
FATP1–6.
FATP1 was discovered by Schaffer and Lodish (119) using an expression cloning strategy and a cDNA library from 3T3-L1 adipocytes to identify a cDNA that, when expressed in cultured cells, augments the uptake of long-chain fatty acids. Subsequently, others identified a family of integral membrane FATPs (FATP2–6) (50, 70). Given the number of FATP isoforms, their transport capacities are likely to vary widely. Zou et al. (145) have examined the role of Fat1p, the FATP1 ortholog in Saccharomyces cerevisiae. This work has shown that Fat1p and a long-chain acyl-CoA synthetase form a functional complex at the plasma membrane, which then couples transport of exogenous fatty acids and their activation (145). Because FATPs share considerable sequence homology and domain organization with acyl-CoA synthetases, there had been concerns that the apparent fatty acid transport function of FATPs merely reflected the long-chain fatty acid activation being coupled to fatty acid metabolism, as opposed to facilitating fatty acid transport per se (33, 112, 115). Although deletion of the Fat1p gene (FAT1) in yeast did not impair the activities of long-chain acyl-CoA synthetases (44), others observed that FAT1 deletion in S. cerevisiae reduced the activity of very long-chain acyl-CoA synthetase activities (142). Purified murine FATP1 and 4 also have acyl-CoA synthetase activities (55, 56), with FATP1 exhibiting a preference for a broad range of fatty acids (55) and FATP4 exhibiting a preference for long- and very long-chain fatty acids (56). Collectively, these studies caused some confusion as to whether the acyl-CoA synthetase activity associated with FATPs provided the driving force for fatty acid transport. However, elegant studies by DiRusso et al. (38) appear to have resolved this matter. They have shown in a genetically defined yeast strain, which normally cannot transport fatty acids and has a reduced acyl-CoA synthetase activity, that FATP1, 2, and 4 are particularly effective in facilitating the rates of long-chain fatty acid transport by 8.2-, 4.5-, and 13.1-fold, respectively, whereas FATP3 and 5 provide only a modest twofold increase, and FATP6 provides virtually no increase in long-chain fatty acid transport (38) (FIGURE 7). Importantly, these FATP-induced increases in fatty acid transport were not attributable to the concurrent upregulation (~1.6-fold) in oleoyl-CoA synthetase activity (38) (FIGURE 7). Others have also cast doubt on a fatty acid transport function for FATP3, since it catalyzes fatty acid activation but not fatty acid transport in MA-10 cells (112). Despite the independent transport functions of FATP1, 2, and 4 (38), it has been found recently that the yeast orthologs of FATP1 and long-chain acyl coenzyme A synthetase 1 co-immunoprecipitated (145) and that FATP1-mediated fatty acid uptake is coupled to long-chain acyl coenzyme A synthetase 1 in 3T3 L1 adipocytes (116).

View larger version (32K): [in this window] [in a new window]   FIGURE 7. Increase in fatty acid transport and oleoyl-CoA synthetase activity Increase in fatty acid (C1-BODIPY-C12) transport and oleoyl-CoA synthetase activity after transfecting murine FATP1-FATP6 into a genetically defined Saccharomyces cerevisiae strain that normally cannot transport fatty acids and has a reduced acyl-CoA synthetase activity. Figure drawn from data published by DiRusso et al. (38).

FAT/CD36.
An 88-kDa adipocyte membrane protein was identified by covalent labeling with N-sulfosuccinimidyl esters of long-chain fatty acids, which irreversibly inhibited fatty acid transport by 75% (63, 64). Subsequently, Abumrad et al. (1) cloned a heavily glycosylated fatty acid translocase (FAT), the sequence of which which was 85% homologous with that of glycoprotein IV (CD36) that had been previously identified in human platelets and in lactating mammary epithelium. Hence, this 88-kDa integral membrane protein is known as FAT/CD36 (1). FAT/CD36 is a class B scavenger receptor protein with multiple functions (46). It is involved in angiogenesis, atherosclerosis, inflammation, as well as lipid metabolism (46). A key role for FAT/CD36 in fatty acid transport was shown when fibroblasts were transfected with FAT/CD36, which resulted in increased rates of fatty acid uptake (3, 74).

	Studies In Vivo

Top Introduction Evidence that Fatty Acids... Critique of Determining Fatty... Defining the Process of... Molecular Evidence for Membrane... Studies In Vitro Studies In Vivo Why so Many Membrane... Do Fatty Acid Transporters... Chronic Regulation of Fatty... Acute Regulation of Fatty... Fatty Acid Transport and... Unsuspected Role of FAT/CD36... Summary References

 
The foregoing studies in vitro have confirmed that a number of distinct proteins facilitate the transport of fatty acids across the plasma membrane. The metabolic consequences of overexpressing or deleting fatty acid transporters in rodents have recently been documented, although the quantitative contributions of fatty acid transport per se to fatty acid metabolism in these models has not always been clarified.

FATP1.
In vivo, FATPs are expressed in somewhat of a tissue-specific manner (40, 70). Transgenic mice with cardiac-specific overexpression of FATP1 demonstrated a fourfold increase in fatty acid uptake (30). This was associated with a twofold increase in cardiomyocyte fatty acid accumulation and in fatty acid metabolism, as well as cardiac dysfunction with pathophysiological findings similar to those in diabetic cardiomyopathy (30). Ablation of FATP1 reduced muscle triacylglycerol content, prevented development of high fat-diet-induced insulin resistance (83), and blunted insulin-stimulated triacylglycerol synthesis (143). Surprisingly, basal rates of fatty acid uptake were not altered (143). We have found that overexpression of FATP1 in rat skeletal muscle increases the rate of long-chain fatty transport into giant sarcolemmal vesicles (111).

FATP2.
FATP2 is expressed mainly in liver and kidney. In these tissues of FATP2-null mice, there was a decreased peroxisomal very long-chain acyl CoA synthetase activity and decreased peroxisomal very long-chain fatty acid -oxidation, but very long-chain fatty acids did not accumulate in liver or kidney (66).

FATP3.
It appears that FATP3 has little or no fatty acid transport function (38, 112). Its effects in vivo have apparently not been explored.

FATP4.
Because it is apparently the only FATP located in the small intestine, FATP4 has been implicated in the absorption of dietary lipids (128). Depending on the means used to ablate FATP4, FATP4-null mice show either an early embryonic (49) or an early neonatal lethality (68, 108). FATP4 does appear to be essential for maintaining normal skin structure and function (67). Deletion of one allele of FATP4 reduced the FATP4 protein by 40–50%, and this was accompanied by a reduced BODIPY-fatty acid uptake in intestinal epithelial cells (49). Overexpression of FATP4 in rat skeletal muscle increases the rate of long-chain fatty transport into giant sarcolemmal vesicles (111).

FATP5.
This protein, FATP5, is present in liver (40, 70). Studies in FATP5-null mice revealed that FATP5 is in hepatic lipid metabolism (39) and to have bile acid CoA synthetase activities (72). In FATP5 knockout mice, fatty acid uptake was reduced 50% in primary hepatocytes, and hepatic triacylglycerol content was reduced. This diminished uptake of fatty acids reduces fatty acid esterification, despite the increased expression of fatty acid synthetase (39).

FATP6.
Recently, it was reported that FATP6 is expressed only in heart (50). Stable transfection of FATP6 into 293 cells enhanced uptake of LCFAs and indicated that the FATP6 isoform is more important than FATP1 for taking up long-chain fatty acids (50). However, there is some debate as to the whether FATP6 has a transport role in rat heart (91), and FATP6 minimally promoted fatty acid uptake when expressed in yeast (38).

Collectively, these studies demonstrate important metabolic functions for many of the FATPs. However, some concerns remain, as in FATP1-null mice, basal rates of fatty acid uptake were not impaired (143), whereas FATP1 overexpression increased fatty acid transport (111). Moreover, the putative, significant transport role for FATP6 (50) has been questioned (38, 91).

FABPpm.
The specific effects of FABPpm on fatty acid transport into mammalian tissue have only been examined in several studies. We (31, 111) have shown that electrotransfecting FABPpm into a single muscle, in vivo, upregulates FABPpm protein within days. It is localized to the plasma membrane and increases the rate of long-chain fatty acid transport into giant sarcolemmal vesicles, as well as increasing fatty acid oxidation but not esterification (31, 111). However, the increase in fatty acid transport (+79%) was far more modest than the increase in plasmalemmal FABPpm (+173%). This may suggest that overexpressing FABPpm alone is not optimally effective for increasing long-chain fatty acid transport rates and that FABPpm may function in conjunction with other fatty acid transporters, particularly FAT/CD36, as some of our recent work has shown (111).

FAT/CD36.
Many studies have now shown that FAT/CD36 is a key, long-chain fatty acid transporter in metabolically important tissues. Under basal conditions, a null mutation in murine FAT/CD36 reduced the uptake of fatty acid analogs in vivo in heart (50–80%), skeletal muscle (40–75%), and adipose tissue (60–70%) (32), and saturable fatty acid transport was lost in adipocytes (45). This reduced rate of fatty acid uptake in FAT/CD36-null mice lowered the basal rates of fatty acid esterification and oxidation in muscle and heart (32, 62, 75, 89). In addition, the metabolic responses (esterification and oxidation) to metabolic challenges provided by insulin, AICAR, and muscle contraction are severely blunted in FAT/CD36-null mice, and their exercise capacity is also markedly reduced (62). Muscle-specific overexpression of FAT/CD36 has shown that fatty acid oxidation was increased in this tissue, but only during muscle contraction, not at rest (73). This suggested to us that long-chain fatty acid transport is not simply regulated by the expression level of FAT/CD36 but possibly also by trafficking this protein to the plasma membrane and/or by activating it at the plasma membrane (see below).

	Why so Many Membrane Fatty Acid Transporters?

Top Introduction Evidence that Fatty Acids... Critique of Determining Fatty... Defining the Process of... Molecular Evidence for Membrane... Studies In Vitro Studies In Vivo Why so Many Membrane... Do Fatty Acid Transporters... Chronic Regulation of Fatty... Acute Regulation of Fatty... Fatty Acid Transport and... Unsuspected Role of FAT/CD36... Summary References

 
Evidence in vitro and in vivo has established clearly that a number of proteins facilitate the cellular entry of long-chain fatty acids. However, the need for so many different fatty acid transporters is not clear. This may reflect different fatty acid transport capacities, congruent with different capacities for fatty acid metabolism in different tissues. Alternatively, it has been suggested that different fatty acid transporters interact with each other to move fatty acids across the plasma membrane (50, 52, 102), since some fatty acid transporters co-immunoprepitate [FAT/CD36 and FATP6 in mouse heart (50), and FAT/CD36 and FABPpm in rat heart (Chabowski and Bonen, unpublished data)]. Functional studies have also shown that blocking either FAT/CD36 or FABPpm is sufficient to markedly inhibit fatty acid transport in heart and skeletal muscle (102, 139), suggesting a close collaboration between these two transporters at the plasma membrane. Since FABPpm is a peripheral membrane protein at the outer leaflet of the plasma membrane (134) and FAT/CD36 is an integral membrane protein (1), we (93, 102) have speculated that FABPpm acts as a receptor for long-chain fatty acids, facilitating the diffusion of the fatty acid-albumin complex through the unstirred fluid layer, and that it then interacts with FAT/CD36 to mediate the transmembrane passage of long-chain fatty acids, possibly by facilitating their flip-flop across the bilayer. In this respect, it should be mentioned that FAT/CD36 has also been reported to interact with FABPc (125). This interaction will facilitate the desorption of fatty acids from the inner plasma membrane leaflet or the intracellular site of the transporter to this intracellular carrier protein.

Another view has been proposed in a recent review by Stahl and Doege (40). They suggested a number of fatty acid transport models, all centered around a key role for FATP in mediating fatty acid transport (40). The proposed models either view FAT/CD36 as interacting with FATPs, possibly by transferring fatty acids from FAT/CD36 to FATPs at the plasma membrane, or alternatively as requiring only FATP (40), while apparently excluding any role for other known fatty acid transporters. As yet, there is no experimental evidence for any of these proposed models. Moreover, the models may not be correct. In the schemes presented, FABPpm has not been included, despite clear evidence that it has a role in fatty acid transport (31, 76, 102, 139). In addition, the possibility of an interaction of FAT/CD36 with FATPs (40, 126) has been challenged (43), largely because convincing experimental work has shown that FATPs and FAT/CD36 are present within distinct plasma membrane compartments (113). Thus, in contrast to one of the proposed schemes (40, 126), such discrete plasmalemmal compartmentation virtually excludes a direct interaction of FATP and FAT/CD36 proteins in mediating fatty acid transport (43). Finally, the proposed models (40, 126) ignore the physiological regulation of fatty acid transporter by fatty acid transporter translocation, particularly FAT/CD36 and FABPpm, as detailed below. Thus recent hypothetical models (40, 126) purporting to describe the regulation of fatty acid transport are far too FATP-centered, while largely ignoring a considerable body of work concerning other fatty acid transporters. Experimental work is needed to discern the interactions of the fatty acid transport proteins in promoting fatty acid transport. In our preliminary work, there is a substantial synergy among fatty acid transporters in stimulating fatty acid transport when several fatty acid transporters are overexpressed simultaneously in skeletal muscle (111).

	Do Fatty Acid Transporters Channel Fatty Acids to a Particular Metabolic Fate?

Top Introduction Evidence that Fatty Acids... Critique of Determining Fatty... Defining the Process of... Molecular Evidence for Membrane... Studies In Vitro Studies In Vivo Why so Many Membrane... Do Fatty Acid Transporters... Chronic Regulation of Fatty... Acute Regulation of Fatty... Fatty Acid Transport and... Unsuspected Role of FAT/CD36... Summary References

 
It has been suggested, based on the overexpression of fatty acid transporters in different cell lines, that specific transport proteins interact with specific intracellular proteins to channel fatty acids to different metabolic fates within the cell (3, 47, 65, 116, 145). Some evidence was recently shown for this in 3T3-L1 adipocytes, in which FATP1 and long-chain acyl coenzyme A synthetase 1 (ACSL1) coimmunoprecipitate (116). Overexpression of ACSL1 increased the rate of fatty acid transport, leading to the conclusion that constitutive interaction between FATP1 and ACSL1 contributes to the efficient cellular uptake of fatty acids in adipocytes through vectorial acylation. This has led to the hypothesis "that fatty acid esterification might be required for fatty acid uptake into adipocytes" (116). Recently, FAT/CD36 was linked with triacylglycerol cycling in C2C12 cells (3). Others have shown a role for ACSL1, 4, and 6 in contributing to fatty acid transport by vectorial acylation (136). Aspects of vectorial acylation have recently been reviewed in detail by Black and DiRusso (9). Despite the attractiveness of fatty acid channeling hypothesis via specific fatty acid transporters, this may apply primarily to cell lines in which normal physiological regulation is absent.

In vivo, fatty acid channeling to a particular metabolic fate via specific fatty acid transporters would not seem to hold, particularly in metabolically dynamic tissues such as skeletal muscle and the heart. Such a scheme ignores the important role of physiological signals to direct fatty acids toward esterification by insulin or to oxidation by muscle contraction. There is already good evidence to indicate that channeling of long-chain fatty acids by FAT/CD36 to triacylglycerols, as observed in C2C12 myotubes (3), does not occur in heart and skeletal muscle. Muscle-specific overexpression of FAT/CD36 in mice failed to increase rates of palmitate esterification or oxidation in isolated skeletal muscle at rest (73). However, in muscle and heart, the contraction- and insulin-induced increases in the sarcolemmal pool of FAT/CD36 (see below) direct long-chain fatty acids to oxidation (13, 73, 97, 103) and esterification (98, 100), respectively. Thus, in vivo, the metabolic fate of long-chain fatty acids that have been transported into heart and muscle is dictated by intracellular signals fashioned by the energetic demands [i.e., contractile activity and AMPK activation (41, 97, 123, 124)] and/or the endocrine milieu [e.g., insulin and leptin (42, 98, 100, 109, 110, 130)].

	Chronic Regulation of Fatty Acid Transport and Transporters

Top Introduction Evidence that Fatty Acids... Critique of Determining Fatty... Defining the Process of... Molecular Evidence for Membrane... Studies In Vitro Studies In Vivo Why so Many Membrane... Do Fatty Acid Transporters... Chronic Regulation of Fatty... Acute Regulation of Fatty... Fatty Acid Transport and... Unsuspected Role of FAT/CD36... Summary References

 
Given the fact that long-chain fatty acid uptake across the plasma membrane is largely protein mediated, the regulation of fatty acid transporters is expected to be a key determinant governing the rate of cellular long-chain fatty acid entry. Therefore, it has been important to establish whether fatty acid transport and transporters are regulated by selected physiological stimuli. A key aspect of this work in our laboratories has been correlating functional measures of fatty acid transport with the subcellular redistribution of fatty acid transporters. Unfortunately, until quite recently, suitable antibodies against rodent FATPs in metabolically important tissues had not been available. Thus, for the most part, we report our work over the past 7 years, in which we have examined the regulation of FABPpm and FAT/CD36 in heart and skeletal muscles by physiological stimuli (see below). Within the past year, we (28, 111) and others (143) have also begun to examine the physiological regulation of FATP1 in vivo.

Perturbations in muscle activity over weeks or days can alter glucose or lactate transport due to changes in the expression of their transporters (77, 104, 107). Similarly, when muscle activity was increased with chronic muscle stimulation (5–7 days), FAT/CD36 protein expression and plasmalemmal content were upregulated, and there was a concomitant increase in the rates of fatty acid transport into giant sarcolemmal vesicles (4, 11, 87) (FIGURE 8). Exercise training also upregulated the fatty acid transport proteins FABPpm and FAT/CD36 (81, 117, 137, 140) and increased palmitate utilization (140). Muscle activity-induced alterations in fatty acid transporters may be mediated by the activation of AMP kinase, since in cardiac myocytes and the heart AMP kinase activation by AICAR upregulates the expression and plasmalemmal content of FAT/CD36 and FABPpm, resulting in an increased rate of fatty acid transport (29).

View larger version (30K): [in this window] [in a new window]   FIGURE 8. Comparison between rates of palmitate transport into giant sarcolemmal vesicles and the protein expression of the fatty acid transporter FAT/CD36 and the plasmalemmal content of FAT/CD36 These experiments demonstrate that experimentally induced up- or downregulation in the rates of palmitate transport into giant sarcolemmal vesicles occurs in direct relation to the up- or downregulation of plasmalemmal FAT/CD36. Importantly, the plasmalemmal levels of FAT/CD36 can be regulated independently of its protein expression, indicating that, under some conditions (denervation and obese Zucker rats), FAT/CD36 is permanently relocated to the plasma membrane. Data are redrawn from studies by Koonen et al. (87), Steinberg et al. (129), and Luiken et al. (96).

View larger version (20K): [in this window] [in a new window]   FIGURE 9. Correlation between altered rates of palmitate transport and altered plasmalemmal FAT/CD36 Correlation between altered rates of palmitate transport and altered plasmalemmal FAT/CD36 in chronically stimulated (7 days) and denervated muscle (7 days) (A), and in red and white muscles of control, pair-fed (14 days) and leptin-treated (14 days) animals (B). In each instance, changes in plasmalemmal FAT/CD36 parallel changes in rates of fatty acid transport into giant sarcolemmal vesicles. Data are redrawn from studies by Koonen et al. (87) (A) and Steinberg et al. (129) (B).

Collectively, our studies have shown that, in heart an skeletal muscle, physiological stimuli alter the protein expression of fatty acid transporters (FAT/CD36 and FABPpm), and due to the concomitant changes in plasmalemmal FAT/CD36 and FABPpm the rates of fatty acid transport are altered accordingly. Importantly, fatty acid transport is not always regulated by changes in the expression of these proteins. At times, their subcellular distribution may be altered independent of changes in their protein expression. It is important to remember that it is the plasmalemmal pool of fatty acid transporters, not the total tissue pool, that regulates the rate of fatty acid transport into the cell.

	Acute Regulation of Fatty Acid Transporters and Transport by Muscle Contraction, AMPK Activation and Insulin

Top Introduction Evidence that Fatty Acids... Critique of Determining Fatty... Defining the Process of... Molecular Evidence for Membrane... Studies In Vitro Studies In Vivo Why so Many Membrane... Do Fatty Acid Transporters... Chronic Regulation of Fatty... Acute Regulation of Fatty... Fatty Acid Transport and... Unsuspected Role of FAT/CD36... Summary References

 
It has long been known that glucose transport is upregulated by insulin and muscle contraction and that insulin stimulates glycogenesis, whereas muscle contraction promotes glucose oxidation (12, 15, 19–21), since these stimuli induce the translocation of the glucose transporter GLUT4 to the plasma membrane (cf. Ref. 53). Similar effects on fatty acid metabolism are provoked by insulin and muscle contraction; in both heart and skeletal muscle, insulin stimulates the rate of fatty acid esterfication (42, 98) and contraction increases the rate of fatty acid oxidation (41, 75). Therefore, we began to examine whether muscle contraction and insulin rapidly upregulated long-chain fatty acid transport by inducing the translocation of one or more fatty acid transporters in a manner analogous to that of the insulin- and contraction-induced GLUT4 translocation.

Muscle contraction.
We have found that FAT/CD36, FABPpm, and FATP1 are located at the plasma membrane and in an intracellular depot in skeletal muscle and in the heart (13, 28, 34, 96–98, 100, 111). During 30 min of muscle contraction, fatty acid transport into giant vesicles was rapidly increased (within 5 min) and continued to increase for the remaining 25 min (FIGURE 10A). On cessation of muscle contraction, the rates of fatty acid transport returned to basal levels during the next 60 min (FIGURE 10A) (13). Blocking plasmalemmal FAT/CD36 with its specific inhibitor, SSO, completely inhibited the contraction-induced increase in palmitate transport into giant vesicles. Interestingly, the rates of palmitate transport into giant sarcolemmal vesicles were increased in direct proportion to the rate of muscle contraction (FIGURE 10B), and kinetic studies showed that Vmax for palmitate transport was increased (FIGURE 10C). Importantly, all these changes in the rates of palmitate transport into giant sarcolemmal vesicles occurred while the palmitate concentration was held constant in the assay. We also observed that the rapid increases and reductions in the rates of fatty acid transport were associated with concomitant increases and reductions in plasmalemmal FAT/CD36, respectively (FIGURE 10D), while at the same time the intracellular FAT/CD36 was altered reciprocally (13). This then was the first study to demonstrate that fatty acid transport could be regulated acutely (i.e., within minutes) due to the translocation of FAT/CD36 from its intracellular depot to the plasma membrane. These observations have now been confirmed by others (138). In more recent work, we have also found that muscle contraction induces the translocation of FABPpm from an intracellular depot to the cell surface (61).

View larger version (36K): [in this window] [in a new window]   FIGURE 10. Palmitate transport into contracting skeletal muscle is upregulated within minutes by inducing the translocation of the fatty acid transporter FAT/CD36 In these studies, skeletal muscle was electrically stimulated for up to 30 min to increase the need for fatty acids to sustain muscle contraction. A: rates of palmitate transport into giant sarcolemmal vesicles were prepared at specific time points during muscle contraction (minutes 0–30, 20 tetani/min) and during recovery from muscle contraction (minutes 30–75). B: rates of palmitate transport into giant sarcolemmal vesicles after 30 min contraction at different contraction rates were designed to progressively increase the need for fatty acids to sustain muscle contraction. C: kinetics of palmitate transport into giant sarcolemmal vesicles are shown after 30 min of contraction at 20 tetani/min. D: plasmalemmal level of FAT/CD36 are shown after 30 min of contraction at 20 tetani/min and after 45 min of recovery from muscle contraction. Data are from Bonen et al. (13).

View larger version (29K): [in this window] [in a new window]   FIGURE 11. Acute regulation of palmitate uptake into cardiac myocytes is regulated differently by AMPK activation and by insulin A: AICAR upregulates the rate of palmitate uptake by inducing the translocation of FAT/CD36 and FABPpm but not FATP1. B: insulin induces the rate of palmitate uptake by inducing the translocation of FAT/CD36 but not FABPpm or FATP1. PM, plasma membrane; IM, intracellular membrane. Data are redrawn from Chabowski et al. (28).

Shortly after our initial reports, Stahl et al. (127) reported that insulin induced the translocation of FATP1 in 3T3-L1 adipocytes (127). Unfortunately, others have had difficulty replicating these results in either 3T3-L1 adipocytes (116) or in cardiac myocytes (28), since insulin failed to induce the translocation of FATP1 in these studies, despite the fact that insulin did stimulate fatty acid uptake in both 3T3-L1 adipocytes (116) and cardiac myocytes (28) (FIGURE 11B). From our work, it is has been clear for some time that the insulin-induced translocation of FAT/CD36 stimulates fatty acid uptake in muscle (61, 62, 98) and heart (28, 100), but in the studies in 3T3-L1 adipocytes (116, 127) the possibility of an insulin-induced translocation of FAT/CD36 was not examined. Given that FATP1 is not induced to translocate by insulin in 3T3-L1 adipocytes (116) and cardiac myocytes (28) and that AMPK activation in cardiac myocytes also fails to induce the translocation of FATP1 (28), the recent report indicating that insulin induces the translocation of FATP1 in skeletal muscle (143) needs to be viewed cautiously. It is at odds with some other studies (28, 116) that have failed to support the idea that FATP1 can be induced to translocate by insulin or by the activation of AMPK.

Signaling of Fatty Acid Transporters.
Ours were the first studies (13, 98, 100) to document the very rapid upregulation of fatty acid transport by the contraction-, AMPK-, and insulin-mediated translocation of selected fatty acid transporters. This regulation of fatty acid transport and fatty acid transporter translocation is remarkably parallel to contraction-, AMPK-, and insulin-induced stimulation of glucose transport into skeletal muscle (cf. Refs. 53, 118). We have recently reviewed these parallel mechanisms in detail elsewhere (cf. Ref. 93). Hence, the signaling pathways involved in mediating fatty acid transporter translocation have become of interest. In FIGURE 12, we have shown schematically the mechanisms, as far as these are known, that induce the translocation of selected fatty acid transporters (FAT/CD36 and FABPpm) in muscle and heart.

View larger version (48K): [in this window] [in a new window]   FIGURE 12. Schematic representation of signaling mechanisms in heart and skeletal muscle that induce the translocation of FAT/CD36 and FABPm from intracellular depots to the plasma membrane, thereby stimulating the rate of fatty acid transport Insulin induces the translocation of FAT/CD36 (and possibly FABPpm in muscle, not heart) from a depot of recycling endosomes to the plasma membrane via the the PI3-kinase-mediated signaling cascade. Involvement of Akt activation is assumed (presently being examined in Akt-null mice). Muscle contraction or AMPK activation by AICAR induces the translocation of FAT/CD36 and FABPpm from a depot of recycling endosomes to the plasma membrane. (FAT/CD36 and FABPpm may be in different intracellular depots). Note also that GLUT4 is induced to translocate by these same stimuli [for detailed review, see Luiken et al. (93)]. Schematic drawing is based on studies published by our group (13, 28, 97, 98, 100) and unpublished work by Han, Chabowski, Glatz, Luiken, and Bonen.

	Fatty Acid Transport and Plasmalemmal FAT/CD36 are Upregulated in Insulin Resistance and Type 2 Diabetes

Top Introduction Evidence that Fatty Acids... Critique of Determining Fatty... Defining the Process of... Molecular Evidence for Membrane... Studies In Vitro Studies In Vivo Why so Many Membrane... Do Fatty Acid Transporters... Chronic Regulation of Fatty... Acute Regulation of Fatty... Fatty Acid Transport and... Unsuspected Role of FAT/CD36... Summary References

	Unsuspected Role of FAT/CD36 in Mitochondrial Fatty Acid Oxidation

Top Introduction Evidence that Fatty Acids... Critique of Determining Fatty... Defining the Process of... Molecular Evidence for Membrane... Studies In Vitro Studies In Vivo Why so Many Membrane... Do Fatty Acid Transporters... Chronic Regulation of Fatty... Acute Regulation of Fatty... Fatty Acid Transport and... Unsuspected Role of FAT/CD36... Summary References

 
Recent work from our laboratory has also shown that FAT/CD36 is located at the mitochondrion, both in rodent (26) and human muscle (7, 71). The reason for its presence in mitochondria is not fully understood. It was observed that blocking FAT/CD36 in isolated mitochondria greatly reduces long-chain, but not short-chain, fatty acid oxidation (26), and during muscle contraction FAT/CD36 is translocated to the mitochondrion (26, 71). FAT/CD36 was found to interact with CPT1 to deliver fatty acyl moieties across the mitochondrial membrane (7). When FAT/CD36 and CPT1 were entered simultaneously in a multiple regression equation, a very strong prediction of fatty acid oxidation in mitochondria was obtained (r = 0.90) (7). This interaction of FAT/CD36 and FATP1 is further supported by their co-immunoprecipitation from skeletal muscle mitochondria (120). How these proteins interact at the mitochondrion to facilitate fatty acid entry into this organelle remains to be determined. Whether impaired mitochondrial FAT/CD36 availability would lead to impairments in fatty acid oxidation remains to be determined. Nevertheless, FAT/CD36 appears to be involved not only with transporting long-chain fatty acids into the muscle cell but also into the mitochondrion where this protein apparently recognizes long-chain fatty-acyl CoAs.

	Summary

Top Introduction Evidence that Fatty Acids... Critique of Determining Fatty... Defining the Process of... Molecular Evidence for Membrane... Studies In Vitro Studies In Vivo Why so Many Membrane... Do Fatty Acid Transporters... Chronic Regulation of Fatty... Acute Regulation of Fatty... Fatty Acid Transport and... Unsuspected Role of FAT/CD36... Summary References

 
There is now considerable evidence that long-chain fatty acids are taken across the plasma membrane by binding to one or more membrane-associated proteins in heart and skeletal muscle and also in adipose tissue. A number of fatty acid transporters have been identified, many of which increase rates of fatty acid transport, including FAT/CD36, FABPpm, FATP1, 2, and 4, and possibly FATP6 in mouse heart but not in rat heart. There is some question whether FATP3 and 5 are fatty acid transporters. In metabolically active tissue (heart and muscle), specific transporters are unlikely to channel fatty acids to a particular metabolic fate, since this is known to be regulated by intracellular metabolic signals provoked by contraction or the endocrine milieu.

It is clear that, in vivo, fatty acid transport in muscle or heart is up- or downregulated in response to changes in plasmalemmal content of fatty acid transporters, particularly FAT/CD36 and/or FABPpm. These plasmalemmal protein changes may or may not reflect changes in their protein expression. In insulin-resistant heart and skeletal muscle, there is a permanent relocation of FAT/CD36 to the plasma membrane, whereas its expression is not altered. A temporary relocation (i.e., translocation) of FAT/CD36 to the plasma membrane, induced by classic physiological stimuli (contraction and insulin), can rapidly and transiently upregulate the rate of long-chain fatty acid transport. FABPpm is induced to translocate selectively by muscle contraction and AMPK activation but not by insulin. There is contradictory evidence as to whether FATP1 is induced to translocate by insulin. Finally, the involvement of FAT/CD36 in mitochondrial fatty acid oxidation is unexpected but further extends the multiple functions of this protein.

Clearly, there is now a wealth of genetic, molecular, biochemical, and physiological evidence to support the idea that fatty acids traverse the plasma membrane via a highly regulated, protein-mediated process, for which a number of proteins have now been identified. We cannot exclude the possibility that additional fatty acid transporters may yet be identified. We concur with Kampf and Kleinfeld (80) that the physical mechanisms of this protein-mediated process, at or within the plasma membrane, remain to be determined. Fatty acid transport and the proteins involved may well differ in tissues such as muscle and adipose tissue, which have very different metabolic roles. The limited understanding of the physical mechanisms of fatty acid per sé, does not invalidate the fact that fatty acid transport across the plasma membrane has repeatedly been shown to occur via a highly regulated protein-mediated process.

	Acknowledgments

 
Studies in our laboratories are supported by grants from the Canadian Institutes of Health Research, the Natural Sciences and Engineering Research Council of Canada, The Heart and Stroke Foundation of Ontario, the Netherlands Heart Foundation (2002T049), the European Community (Integrated Project LSHM-CT-2004-005272, Exgenesis), and the Canada Research Chair program. J.J.F.P. Luiken is a recipient of a VIDI-Innovation Research Grant from the Netherlands Organization for Scientific Research (NWO-ZonMw Grant 016.036.305). J.F.C. Glatz is Netherlands Heart Foundation Professor of Cardiac Metabolism. A. Bonen is the Canada Research Chair in Metabolism and Health.

	References

Top Introduction Evidence that Fatty Acids... Critique of Determining Fatty... Defining the Process of... Molecular Evidence for Membrane... Studies In Vitro Studies In Vivo Why so Many Membrane... Do Fatty Acid Transporters... Chronic Regulation of Fatty... Acute Regulation of Fatty... Fatty Acid Transport and... Unsuspected Role of FAT/CD36... Summary References

 

1. Abumrad NA, El-Maghrabi MR, Amri EZ, Lopez E, Grimaldi P. Cloning of a rat adipocyte membrane protein implicated in binding or transport of long chain fatty acids that is induced during preadipocyte differentiation. Homology with human CD36. J Biol Chem 268: 17665–17668, 1993.[Abstract/Free Full Text]
2. Abumrad NA, Perkins RC, Park JH, Park CR. Mechanism of long chain fatty acid permeation in the isolated adipocyte. J Biol Chem 256: 9183–9191, 1981.[Free Full Text]
3. Bastie CC, Hajri T, Drover VA, Grimaldi PA, Abumrad NA. CD36 in myocytes channels fatty acids to a lipase-accessible triglyceride pool that is related to cell lipid and insulin responsiveness. Diabetes 53: 2209–2216, 2004.[Abstract/Free Full Text]
4. Benton CR, Koonen DP, Calles-Escandon J, Tandon NN, Glatz JFC, Luiken JJFP, Heikkila JJ, Bonen A. Differential effects of muscle contraction and PPAR agonists on the expression of fatty acid transporters in rat skeletal muscle. J Physiol 573: 199–210, 2006.[Abstract/Free Full Text]
5. Berk PD, Zhou SL, Kiang CL, Stump D, Bradbury M, Isola L. Uptake of long chain fatty acids is selectively up-regulated in adipocytes of Zucker rats with genetic obesity and non-insulin-dependent diabetes mellitus. J Biol Chem 272: 8830–8835, 1997.[Abstract/Free Full Text]
6. Berk PD, Zhou SL, Kiang CL, Stump D, Fan X, Bradbury M. Selective upregulation of fatty acid uptake by adipocytes characterizes both genetic and diet-induced obesity in rodents. J Biol Chem 274: 28626–28631, 1999.[Abstract/Free Full Text]
7. Bezaire V, Bruce CR, Heigenhauser GJ, Tandon NN, Glatz JF, Luiken JJ, Bonen A, Spriet LL. Identification of fatty acid translocase on human skeletal muscle mitochondrial membranes: essential role in fatty acid oxidation. Am J Physiol Endocrinol Metab 290: E509–E515, 2006.[Abstract/Free Full Text]
8. Binnert C, Koistinen HA, Martin G, Andreelli F, Ebeling P, Koivisto VA, Laville M, Auwerx J, Vidal H. Fatty acid transport protein-1 mRNA expression in skeletal muscle and in adipose tissue in humans. Am J Physiol Endocrinol Metab 279: E1072–E1079, 2000.[Abstract/Free Full Text]
9. Black PN, Dirusso CC. Yeast acyl-CoA synthetases at the crossroads of fatty acid metabolism and regulation. Biochim Biophys Acta. In press.
10. Bonen A, Campbell SE, Benton CR, Chabowski A, Coort SL, Han XX, Koonen DP, Glatz JF, Luiken JJ. Regulation of fatty acid transport by fatty acid translocase/CD36. Proc Nutr Soc 63: 245–249, 2004.[CrossRef][Web of Science][Medline]
11. Bonen A, Dyck DJ, Ibrahimi A, Abumrad NA. Muscle contractile activity increases fatty acid metabolism and transport and FAT/CD36. Am J Physiol Endocrinol Metab 276: E642–E649, 1999.[Abstract/Free Full Text]
12. Bonen A, Elder GCB, Tan MH. Hindlimb suspension increases insulin binding and glucose metabolism. J Appl Physiol 65: 1833–1839, 1988.[Abstract/Free Full Text]
13. Bonen A, Luiken JJFP, Arumugam Y, Glatz JFC, Tandon NN. Acute regulation of fatty acid uptake involves the cellular redistribution of fatty acid translocase. J Biol Chem 275: 14501–14508, 2000.[Abstract/Free Full Text]
14. Bonen A, Luiken JJFP, Lui S, Dyck DJ, Kiens B, Kristiansen S, Turcotte L, van der Vusse GJ, Glatz JFC. Palmitate transport and fatty acid transporters in red and white muscles. Am J Physiol Endocrinol Metab 275: E471–E478, 1998.[Abstract/Free Full Text]
15. Bonen A, McDermott JC, Tan MH. Glycogenesis and glyconeogenesis in skeletal muscle: effects of pH and hormones. Am J Physiol Endocrinol Metab 258: E693–E700, 1990.[Abstract/Free Full Text]
16. Bonen A, Miskovic D, Kiens B. Fatty acid transporters (FABPpm, FAT, FATP) in human muscle. Can J Appl Physiol 24: 515–523, 1999.[Web of Science][Medline]
17. Bonen A, Miskovic D, Tonouchi M, Lemieux K, Wilson MC, Marette A, Halestrap AP. Abundance and subcellular distribution of MCT1 and MCT4 in heart and fast-twitch skeletal muscles. Am J Physiol Endocrinol Metab 278: E10667–E11077, 2000.
18. Bonen A, Parolin ML, Steinberg GR, Calles-Escandon J, Tandon NN, Glatz JFC, Luiken JJFP, Heigenhauser GJF, Dyck DJ. Triacylglycerol accumulation in human obesity and Type 2 diabetes is associated with increased rates of skeletal muscle fatty acid transport and increased sarcolemmal FAT/CD36. FASEB J 18: 1144–1146, 2004.[Abstract/Free Full Text]
19. Bonen A, Tan MH. Dissociation between insulin binding and glucose utilization after intense exercise in mouse skeletal muscles. Horm Metab Res 21: 172–178, 1989.[Web of Science][Medline]
20. Bonen A, Tan MH, Megeney LA, McDermott JC. Persistence of glucose metabolism after exercise in trained and untrained soleus muscle. Diabetes Care 15, Suppl 4: 1694–1700, 1992.[Abstract]
21. Bonen A, Tan MH, Watson-Wright WM. Effects of exercise on insulin binding and glucose metabolism in muscle. Can J Physiol Pharm 62: 1500–1504, 1984.[Web of Science][Medline]
22. Bonen A, Tandon NN, Glatz JF, Luiken JJ, Heigenhauser GJ. The fatty acid transporter FAT/CD36 is upregulated in subcutaneous and visceral adipose tissues in human obesity and type 2 diabetes. Int J Obes (Lond) 30: 877–883, 2006.[CrossRef][Web of Science][Medline]
23. Bradbury MW, Berk PD. Mitochondrial aspartate aminotransferase: direction of a single protein with two distinct functions to two subcellular sites does not require alternative splicing of the mRNA. Biochem J 345: 423–427, 2000.[CrossRef][Web of Science][Medline]
24. Bruce CR, Anderson MJ, Carey AL, Newman DG, Bonen A, Kriketos AD, Cooney GJ, Hawley JA. Muscle oxidative capacity is a better predictor of insulin sensitivity than lipid status. J Clin Endocrinol Metab 88: 5444–5451, 2003.[Abstract/Free Full Text]
25. Cameron-Smith D, Burke LM, Angus DJ, Tunstall RJ, Cox GR, Bonen A, Hawley JA, Hargreaves M. A short-term, high-fat diet up-regulates lipid metabolism and gene expression in human skeletal muscle. Am J Clin Nutr 77: 313–318, 2003.[Abstract/Free Full Text]
26. Campbell SE, Tandon NN, Woldegiorgis G, Luiken JJFP, Glatz JFC, Bonen A. A novel function for FAT/CD36: involvement in long chain fatty acid transfer into the mitochondria. J Biol Chem 279: 36325–36341, 2004.
27. Chabowski A, Coort SL, Calles-Escandon J, Tandon NN, Glatz JF, Luiken JJ, Bonen A. Insulin stimulates fatty acid transport by regulating expression of FAT/CD36 but not FABPpm. Am J Physiol Endocrinol Metab 287: E781–E789, 2004.[Abstract/Free Full Text]
28. Chabowski A, Coort SLM, Calles-Escandon J, Tandon NN, Glatz JFC, Luiken JJFP, Bonen A. The subcellular compartmentation of fatty acid transporters is regulated differently by insulin and by AICAR. FEBS Lett 579: 2428–2432, 2005.[CrossRef][Web of Science][Medline]
29. Chabowski A, Momken I, Coort SLM, Calles-Escandon J, Tandon NN, Glatz JFC, Luiken JJFP, Bonen A. Prolonged AMPK activation increases the expression of fatty acid transporters in cardiac myocytes and perfused hearts. Mol Cell Biochem 288: 201–212, 2006.[CrossRef][Web of Science][Medline]
30. Chiu HC, Kovacs A, Blanton RM, Han X, Courtois M, Weinheimer CJ, Yamada KA, Brunet S, Xu H, Nerbonne JM, Welch MJ, Fettig NM, Sharp TL, Sambandam N, Olson KM, Ory DS, Schaffer JE. Transgenic expression of fatty acid transport protein 1 in the heart causes lipotoxic cardiomyopathy. Circ Res 96: 225–233, 2005.[Abstract/Free Full Text]
31. Clarke DC, Miskovic D, Han XX, Calles-Escandon J, Glatz JFC, Luiken JJFP, Heikkila JJ, Bonen A. Overexpression of membrane associated fatty acid binding protein (FABPpm) in vivo increases fatty acid sarcolemmal transport and metabolism. Physiol Genomics 17: 31–37, 2004.[Abstract/Free Full Text]
32. Coburn CT, Knapp FF Jr, Febbraio M, Beets AL, Silverstein RL, Abumrad NA. Defective uptake and utilization of long chain fatty acids in muscle and adipose tissue of CD36 knockout mice. J Biol Chem 275: 32523–32529, 2000.[Abstract/Free Full Text]
33. Coe NR, Smith AJ, Frohnert BI, Watkins PA, Bernlohr DA. The fatty acid transport protein (FATP1) is a very long chain acyl-CoA synthetase. J Biol Chem 274: 36300–36304, 1999.[Abstract/Free Full Text]
34. Coort SL, Luiken JJ, Van Der Vusse GJ, Bonen A, Glatz JF. Increased FAT (fatty acid translocase)/CD36-mediated long-chain fatty acid uptake in cardiac myocytes from obese Zucker rats. Biochem Soc Trans 32: 83–85, 2004.[CrossRef][Web of Science][Medline]
35. Coort SLM, Hasselbaink DM, Koonen DYP, Willems J, Coumans WA, Chabowski A, van der Vusse GJ, Bonen A, Glatz JFC, Luiken JJFP. Enhanced sarcolemmal FAT/CD36 content and triacylglycerol storage in cardiac myocytes from obese Zucker rats. Diabetes 53: 1655–1663, 2004.[Abstract/Free Full Text]
36. Cupp D, Kampf JP, Kleinfeld AM. Fatty acid-albumin complexes and the determination of the transport of long chain free fatty acids across membranes. Biochemistry 43: 4473–4481, 2004.[CrossRef][Medline]
37. Diede HE, Rodilla-Sala E, Gunawan J, Manns M, Stremmel W. Identification and characterization of a monoclonal antibody to the membrane fatty acid binding protein. Biochim Biophys Acta 1125: 13–20, 1992.[Medline]
38. DiRusso CC, Li H, Darwis D, Watkins PA, Berger J, Black PN. Comparative biochemical studies of the murine fatty acid transport proteins (FATP) expressed in yeast. J Biol Chem 280: 16829–16837, 2005.[Abstract/Free Full Text]
39. Doege H, Baillie RA, Ortegon AM, Tsang B, Wu Q, Punreddy S, Hirsch D, Watson N, Gimeno RE, Stahl A. Targeted deletion of FATP5 reveals multiple functions in liver metabolism: alterations in hepatic lipid homeostasis. Gastroenterology 130: 1245–1258, 2006.[CrossRef][Web of Science][Medline]
40. Doege H, Stahl A. Protein-mediated fatty acid uptake: novel insights from in vivo models. Physiology 21: 259–268, 2006.[Abstract/Free Full Text]
41. Dyck DJ, Bonen A. Muscle contraction increases palmitate esterification and oxidation, and triacyl-glycerol oxidation. Am J Physiol Endocrinol Metab 275: E888–E896, 1998.[Abstract/Free Full Text]
42. Dyck DJ, Steinberg G, Bonen A. Insulin increases FFA uptake and esterification but reduces lipid utilization in isolated contracting muscles. Am J Physiol Endocrinol Metab 281: E600–E607, 2001.[Abstract/Free Full Text]
43. Ehehalt R, Fullekrug J, Pohl J, Ring A, Herrmann T, Stremmel W. Translocation of long chain fatty acids across the plasma membrane: lipid rafts and fatty acid transport proteins. Mol Cell Biochem 284: 135–140, 2006.[CrossRef][Web of Science][Medline]
44. Faergeman NJ, DiRusso CC, Elberger A, Knudsen J, Black PN. Disruption of the Saccharomyces cerevisiae homologue to the murine fatty acid transport protein impairs uptake and growth on long-chain fatty acids. J Biol Chem 272: 8531–8538, 1997.[Abstract/Free Full Text]
45. Febbraio M, Abumrad NA, Hajjar DP, Sharma K, Cheng W, Frieda S, Pearce A, Silverstein RL. A null mutation in murine CD36 reveals an important role in fatty acid and lipoprotein metabolism. J Biol Chem 274: 19055–19062, 1999.[Abstract/Free Full Text]
46. Febbraio M, Hajjar DP, Silverstein RL. CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J Clin Invest 108: 785–791, 2001.[CrossRef][Web of Science][Medline]
47. Gargiulo CE, Stuhlsatz-Krouper SM, Schaffer JE. Localization of adipocyte long-chain fatty acyl CoA synthetase at the plasma membrane. J Lipid Res 40: 881–892, 1999.[Abstract/Free Full Text]
48. Gertow K, Pietilainen KH, Yki-Jarvinen H, Kaprio J, Rissanen A, Eriksson P, Hamsten A, Fisher RM. Expression of fatty-acid-handling proteins in human adipose tissue in relation to obesity and insulin resistance. Diabetologia 47: 1118–1125, 2004.[Web of Science][Medline]
49. Gimeno RE, Hirsch DJ, Punreddy S, Sun Y, Ortegon AM, Wu H, Daniels T, Stricker-Krongrad A, Lodish HF, Stahl A. Targeted deletion of fatty acid transport protein-4 results in early embryonic lethality. J Biol Chem 278: 49512–49516, 2003.[Abstract/Free Full Text]
50. Gimeno RE, Ortegon AM, Patel S, Punreddy S, Ge P, Sun Y, Lodish HF, Stahl A. Characterization of a heart-specific fatty acid transport protein. J Biol Chem 278: 16039–16044, 2003.[Abstract/Free Full Text]
51. Glatz JFC, Luiken J, Bonen A. Exercise and insulin increase muscle fatty acid uptake by recruiting putative fatty acid transporters to the sarcolemma. Curr Opin Clin Nutr Metab Care 5: 365–370, 2002.[CrossRef][Web of Science][Medline]
52. Glatz JFC, Storch J. Unravelling the significance of cellular fatty acid binding proteins. Curr Opin Lipidol 12: 267–274, 2001.[CrossRef][Web of Science][Medline]
53. Goodyear LJ, Kahn BB. Exercise, glucose transport, and insulin sensitivity. Ann Rev Med 49: 235–261, 1998.[CrossRef][Web of Science][Medline]
54. Hajri T, Han XX, Bonen A, Abumrad NA. Defective fatty acid uptake modulates insulin responsiveness and metabolic responses to diet in CD36-null mice. J Clin Invest 109: 1381–1389, 2002.[CrossRef][Web of Science][Medline]
55. Hall AM, Smith AJ, Bernlohr DA. Characterization of the Acyl-CoA synthetase activity of purified murine fatty acid transport protein 1. J Biol Chem 278: 43008–43013, 2003.[Abstract/Free Full Text]
56. Hall AM, Wiczer BM, Herrmann T, Stremmel W, Bernlohr DA. Enzymatic properties of purified murine fatty acid transport protein 4 and analysis of acyl-CoA synthetase activities in tissues from FATP4 null mice. J Biol Chem 280: 11948–11954, 2005.[Abstract/Free Full Text]
57. Hamilton J, Guo W, Kamp F. Mechanisms of cellular uptake of long-chain fatty acids: do we need cellular proteins? Mol Cell Biochem 239: 17–23, 2002.
58. Hamilton JA. Fatty acid transport: difficult or easy? J Lipid Res 39: 467–481, 1998.
59. Hamilton JA, Johnson RA, Corkey B, Kamp F. Fatty acid transport: the diffusion mechanism in model and biological membranes. J Mol Neurosci 16: 99–108; discussion 151–107, 2001.[CrossRef][Web of Science][Medline]
60. Hamilton JA, Kamp F. How are free fatty acids transported in membranes? Is it by proteins or by free diffusion through the lipids? Diabetes 48: 2255–2269, 1999.
61. Han XX, Chabowski A, Glatz JFC, Luiken JJFP, Bonen A. Fatty acid metabolism and FAT/CD36 translocation are resistant to insulin in skeletal muscle of obese Zucker rats. In: Keystone Symposium: Molecular Physiology and Genetics of the Control of Body Weight. Keystone, Colorado, 2005, p. 114.
62. Han XX, Febbraio M, Bonen A. Critical role of FAT/CD36 in regulating fatty acid metabolism in skeletal muscle. FASEB J: A1006, 2005.
63. Harmon CM, Abumrad NA. Binding of sulfosuccinimidyl fatty acids to adipocyte membrane proteins: isolation and amino-terminal sequence of an 88-kD protein implicated in transport of long-chain fatty acids. J Membr Biol 133: 43–49, 1993.[Web of Science][Medline]
64. Harmon CM, Luce P, Beth AH, Abumrad NA. Labeling of adipocyte membranes by sulfo-N-succinimidyl derivatives of long-chain fatty acids: inhibition of fatty acid transport. J Membr Biol 121: 261–268, 1991.[CrossRef][Web of Science][Medline]
65. Hatch GM, Smith AJ, Xu FY, Hall AM, Bernlohr DA. FATP1 channels exogenous FA into 1,2,3-tri-acyl-sn-glycerol and down-regulates sphin-gomyelin and cholesterol metabolism in growing 293 cells. J Lipid Res 43: 1380–1389, 2002.[Abstract/Free Full Text]
66. Heinzer AK, Watkins PA, Lu JF, Kemp S, Moser AB, Li YY, Mihalik S, Powers JM, Smith KD. A very long-chain acyl-CoA synthetase-deficient mouse and its relevance to X-linked adrenoleukodystrophy. Hum Mol Genet 12: 1145–1154, 2003.[Abstract/Free Full Text]
67. Herrmann T, Grone HJ, Langbein L, Kaiser I, Gosch I, Bennemann U, Metzger D, Chambon P, Stewart AF, Stremmel W. Disturbed epidermal structure in mice with temporally controlled fatp4 deficiency. J Invest Dermatol 125: 1228–1235, 2005.[CrossRef][Web of Science][Medline]
68. Herrmann T, van der Hoeven F, Grone HJ, Stewart AF, Langbein L, Kaiser I, Liebisch G, Gosch I, Buchkremer F, Drobnik W, Schmitz G, Stremmel W. Mice with targeted disruption of the fatty acid transport protein 4 (Fatp 4, Slc27a4) gene show features of lethal restrictive dermopathy. J Cell Biol 161: 1105–1115, 2003.[Abstract/Free Full Text]
69. Hirano K, Kuwasako T, Nakagawa-Toyama Y, Janabi M, Yamashita S, Matsuzawa Y. Pathophysiology of human genetic CD36 deficiency. Trends Cardiovasc Med 13: 136–141, 2003.[CrossRef][Web of Science][Medline]
70. Hirsch D, Stahl A, Lodish HF. A family of fatty acid transporters conserved from mycobacterium to man. Proc Natl Acad Sci USA 95: 8625–8629, 1998.[Abstract/Free Full Text]
71. Holloway GP, Bezaire V, Heigenhauser GJ, Tandon NN, Glatz JF, Luiken JJ, Bonen A, Spriet LL. Mitochondrial long chain fatty acid oxidation, fatty acid translocase/CD36 content and carnitine palmitoyltransferase 1 activity in human skeletal muscle during aerobic exercise. J Physiol 571: 201–210, 2006.[Abstract/Free Full Text]
72. Hubbard B, Doege H, Punreddy S, Wu H, Huang X, Kaushik VK, Mozell RL, Byrnes JJ, Stricker-Krongrad A, Chou CJ, Tartaglia LA, Lodish HF, Stahl A, Gimeno RE. Mice deleted for fatty acid transport protein 5 have defective bile acid conjugation and are protected from obesity. Gastroenterology 130: 1259–1269, 2006.[CrossRef][Web of Science][Medline]
73. Ibrahimi A, Bonen A, Blinn WD, Hajri T, Li X, Zhong K, Cameron R, Abumrad NA. Muscle-specific overexpression of FAT/CD36 enhances fatty acid oxidation by contracting muscles, reduces plasma triglycerides and fatty acids, and increases plasma glucose and insulin. J Biol Chem 274: 26761–26766, 1999.[Abstract/Free Full Text]
74. Ibrahimi A, Sfeir Z, Magharaine H, Amri EZ, Grimaldi P, Abumrad NA. Expression of the CD36 homolog (FAT) in fibroblast cells: effects on fatty acid transport. Proc Natl Acad Sci USA 93: 2646–2651, 1996.[Abstract/Free Full Text]
75. Irie H, Krukenkamp IB, Brinkmann JF, Gaudette GR, Saltman AE, Jou W, Glatz JF, Abumrad NA, Ibrahimi A. Myocardial recovery from ischemia is impaired in CD36-null mice and restored by myocyte CD36 expression or medium-chain fatty acids. Proc Natl Acad Sci USA 100: 6819–6824, 2003.[Abstract/Free Full Text]
76. Isola LM, Zhou SL, Kiang CL, Stump DD, Bradbury MW, Berk PD. 3T3 fibroblasts transfected with a cDNA for mitochondrial aspartate aminotransferase express plasma membrane fatty acid-binding protein and saturable fatty acid uptake. Proc Natl Acad Sci USA 92: 9866–9870, 1995.[Abstract/Free Full Text]
77. Johannsson E, McCullagh KJA, Han X, Fernando PK, Jensen J, Dahl HA, Bonen A. Effect of over-expressing GLUT-1 and GLUT-4 on insulin- and contraction stimulated glucose transport in muscle. Am J Physiol Endocrinol Metab 271: E547–E555, 1996.[Abstract/Free Full Text]
78. Kampf JP, Cupp D, Kleinfeld AM. Different mechanisms of free fatty acid flip-flop and dissociation revealed by temperature and molecular species dependence of transport across lipid vesicles. J Biol Chem 281: 21566–21574, 2006.[Abstract/Free Full Text]
79. Kampf JP, Kleinfeld AM. Fatty acid transport in adipocytes monitored by imaging intracellular free fatty acid levels. J Biol Chem 279: 35775–35780, 2004.[Abstract/Free Full Text]
80. Kampf JP, Kleinfeld AM. Membrane transport of FFA mediated by lipid, protein, or both? Physiology 22: xxxx, 2006.
81. Kiens B, Kristiansen S, Jensen P, Richter EA, Turcotte LP. Membrane associated fatty acid binding protein (FABPpm) in human skeletal muscle is increased by endurance training. Biochem Biophys Res Comm 231: 463–465, 1997.[CrossRef][Web of Science][Medline]
82. Kiens B, Roemen TH, van der Vusse GJ. Muscular long-chain fatty acid content during graded exercise in humans. Am J Physiol Endocrinol Metab 276: E352–E357, 1999.[Abstract/Free Full Text]
83. Kim JK, Gimeno RE, Higashimori T, Kim HJ, Choi H, Punreddy S, Mozell RL, Tan G, Stricker-Krongrad A, Hirsch DJ, Fillmore JJ, Liu ZX, Dong J, Cline G, Stahl A, Lodish HF, Shulman GI. Inactivation of fatty acid transport protein 1 prevents fat-induced insulin resistance in skeletal muscle. J Clin Invest 113: 756–763, 2004.[CrossRef][Web of Science][Medline]
84. Kim YB, Shulman GI, Kahn BB. Fatty acid infusion selectively impairs insulin action on Akt1 and protein kinase C ?«unknown symbol»? but not on glycogen synthase kinase-3. J Biol Chem 277: 32915–32922, 2002.[Abstract/Free Full Text]
85. King PA, Hirschman MF, Horton ED, Horton ES. Glucose transport in skeletal muscle membrane vesicles from control and exercised rats. Am J Physiol 257: C1128–C1134., 1989.[Web of Science][Medline]
86. Koonen DP, Glatz JF, Bonen A, Luiken JJ. Long-chain fatty acid uptake and FAT/CD36 translocation in heart and skeletal muscle. Biochim Biophys Acta 1736: 163–180, 2005.[Medline]
87. Koonen DPY, Benton CR, Arumugam Y, Tandon NN, Calles-Escandon J, Glatz JFC, Luiken JJFP, Bonen A. Different mechanism can alter fatty acid transport when muscle contractile activity is chronically altered. Am J Physiol Endocrinol Metab 286: E1042–E1049, 2004.[Abstract/Free Full Text]
88. Koonen DPY, Coumans WA, Arumugam Y, Bonen A, Glatz JFC, Luiken JJFP. Giant membrane vesicles as a model to study cellular substrate uptake dissected from metabolism. Mol Cell Biochem 239: 121–130, 2002.[CrossRef][Web of Science][Medline]
89. Kuang M, Febbraio M, Wagg C, Lopaschuk GD, Dyck JR. Fatty acid translocase/CD36 deficiency does not energetically or functionally compromise hearts before or after ischemia. Circulation 109: 1550–1557, 2004.[Abstract/Free Full Text]
90. Lauritzen HP, Ploug T, Prats C, Tavare JM, Galbo H. Imaging of insulin signaling in skeletal muscle of living mice shows major role of T-tubules. Diabetes 55: 1300–1306, 2006.[Abstract/Free Full Text]
91. Lavrentyev EN, He D, Cook GA. Mistaken identity or yet another case of species difference? Am J Physiol Heart Circ Physiol 288: H448–H450, 2005.
92. Lemieux K, Han XX, Dombrowski L, Bonen A, Marette A. The transferrin receptor defines two distinct contraction-responsive GLUT4 vesicle populations. Diabetes 49: 183–189, 2000.[Abstract]
93. Luiken JJ, Coort SL, Koonen DP, van der Horst DJ, Bonen A, Zorzano A, Glatz JF. Regulation of cardiac long-chain fatty acid and glucose uptake by translocation of substrate transporters. Pflugers Arch 448: 1–15, 2004.[CrossRef][Web of Science][Medline]
94. Luiken JJ, Coort SL, Willems J, Coumans WA, Bonen A, Glatz JF. Dipyridamole alters cardiac substrate preference by inducing translocation of FAT/CD36, but not that of GLUT4. Mol Pharmacol 65: 639–645, 2004.[Abstract/Free Full Text]
95. Luiken JJ, Willems J, Coort SL, Coumans WA, Bonen A, Van Der Vusse GJ, Glatz JF. Effects of cAMP modulators on long-chain fatty-acid uptake and utilization by electrically stimulated rat cardiac myocytes. Biochem J 367: 881–887, 2002.[CrossRef][Web of Science][Medline]
96. Luiken JJFP, Arumugam Y, Dyck DJ, Bell RC, Pelsers ML, Turcotte LP, Tandon NN, Glatz JFC, Bonen A. Increased rates of fatty acid uptake and plasmalemmal fatty acid transporters in obese Zucker rats. J Biol Chem 276: 40567–40573, 2001.[Abstract/Free Full Text]
97. Luiken JJFP, Coort SML, Willems J, Coumans WA, Bonen A, van der Vusse GJ, Glatz JFC. Contraction-induced fatty acid translocase/CD36 translocation in rat cardiac myocytes is mediated through AMP-activated protein kinase signaling. Diabetes 52: 1627–1634, 2003.[Abstract/Free Full Text]
98. Luiken JJFP, Dyck DJ, Han XX, Tandon NN, Arumugam Y, Glatz JFC, Bonen A. Insulin induces the translocation of the fatty acid transporter FAT/CD36 to the plasma membrane. Am J Physiol Endocrinol Metab 282: E491–E495, 2002.[Abstract/Free Full Text]
99. Luiken JJFP, Koonen DPY, Coumans WA, Pelsers MMAL, Binas B, Bonen A, Glatz JFC. Long chain fatty acid uptake by skeletal muscles is impaired in homozygous, but not heterozygous, H-FABP null mice. Lipids 38: 491–496, 2003.[Web of Science][Medline]
100. Luiken JJFP, Koonen DPY, Willems J, Zorzano A, Fischer Y, van der Vusse GJ, Bonen A, Glatz JFC. Insulin stimulates long-chain fatty acid uilization by rat cardiac myocytes through cellular redistribution of FAT/CD36. Diabetes 51: 3113–3119, 2002.[Abstract/Free Full Text]
101. Luiken JJFP, Momken I, Habets D, Pelsers MMAL, Coumans WA, Koonen DPY, Glatz JFC, Bonen A. Arsenite modulates cardiac substrate preference by translocation of GLUT4, but not of CD36 independent of MAPK signaling. Endocrinology. In press.
102. Luiken JJFP, Turcotte LP, Bonen A. Protein-mediated palmitate uptake and expression of fatty acid transport proteins in heart giant vesicles. J Lipid Res 40: 1007–1016, 1999.[Abstract/Free Full Text]
103. Luiken JJFP, Willems J, van der Vusse GJ, Glatz JFC. Electrostimulation enhances FAT/CD36-mediated long-chain fatty acid uptake by isolated rat cardiac myocytes. Am J Physiol Endocrinol Metab 281: E704–E712, 2001.[Abstract/Free Full Text]
104. McCullagh KJA, Juel C, O’Brien M, Bonen A. Chronic muscle stimulation increases lactate transport in rat skeletal muscle. Mol Cell Biochem 156: 51–57, 1996.[CrossRef][Web of Science][Medline]
105. McDermott JC, Bonen A. Lactate transport by skeletal muscle sarcolemmal vesicles. Mol Cell Biochem 122: 113–121, 1993.[CrossRef][Web of Science][Medline]
106. McDermott JC, Bonen A. Lactate transport in rat sarcolemmal vesicles and intact skeletal muscle, and after muscle contraction. Acta Physiol Scand 151: 17–28, 1994.[Web of Science][Medline]
107. Megeney LA, Neufer PD, Dohm GL, Tan MH, Blewett CA, Elder GCB, Bonen A. Effects of muscle activity and fiber composition on glucose transport and GLUT-4. Am J Physiol Endocrinol Metab 264: E583–E593, 1993.[Abstract/Free Full Text]
108. Moulson CL, Martin DR, Lugus JJ, Schaffer JE, Lind AC, Miner JH. Cloning of wrinkle-free, a previously uncharacterized mouse mutation, reveals crucial roles for fatty acid transport protein 4 in skin and hair development. Proc Natl Acad Sci USA 100: 5274–5279, 2003.[Abstract/Free Full Text]
109. Muoio DM, Dohm GL, Fiedorek FT, Tapscott EB Jr, Coleman RA. Leptin directly alters lipid par-tioning in skeletal muscle. Diabetes 46: 1360–1363, 1997.[Abstract]
110. Muoio DM, Dohm GL, Tapscott EB, Coleman RA. Leptin opposes insulin’s effects on fatty acid partitioning in muscles isolated from obese ob/ob mice. Am J Physiol Endocrinol Metab 276: E913–E921, 1999.[Abstract/Free Full Text]
111. Nickerson J, Bonen A. Defining a role for skeletal muscle fatty acid transport proteins. In: 2nd Northern Lights Conference. Canadian Federation of Biological Societies. Guelph, Ontario, Canada: Canadian Federation of Biological Societies, 2005, p. F47.
112. Pei Z, Fraisl P, Berger J, Jia Z, Forss-Petter S, Watkins PA. Mouse very long-chain acyl-CoA syn-thetase3/fatty acid transport protein 3 catalyzes fatty acid activation but not fatty acid transport in MA-10 cells. J Biol Chem 279: 54454–54462, 2004.[Abstract/Free Full Text]
113. Pohl J, Ring A, Korkmaz U, Ehehalt R, Stremmel W. FAT/CD36-mediated long-chain fatty acid uptake in adipocytes requires plasma membrane rafts. Mol Biol Cell 16: 24–31, 2005.[Abstract/Free Full Text]
114. Rachek LI, Musiyenko SI, Ledoux SP, Wilson GL. Palmitate induced mtDNA damage and apoptosis in L6 rat skeletal muscle cells. Endocrinology. In press.
115. Ribarik Coe N, Johnston Smith A, Frohnert BI, Watkins PA, Bernlohr DA. The fatty acid transport protein (FATP1) is a very long chain acyl-CoA synthetase. J Biol Chem 274: 36300–36304, 1999.[Abstract/Free Full Text]
116. Richards MR, Harp JD, Ory DS, Schaffer JE. Fatty acid transport protein 1 and long-chain acyl coenzyme A synthetase 1 interact in adipocytes. J Lipid Res 47: 665–672, 2006.[Abstract/Free Full Text]
117. Roepstorff C, Vistisen B, Roepstorff K, Kiens B. Regulation of plasma long-chain fatty acid oxidation in relation to uptake in human skeletal muscle during exercise. Am J Physiol Endocrinol Metab 287: E696–E705, 2004.[Abstract/Free Full Text]
118. Sakamoto K, Goodyear LJ. Invited review: intracellular signaling in contracting skeletal muscle. J Appl Physiol 93: 369–383, 2002.[Abstract/Free Full Text]
119. Schaffer JE, Lodish HF. Expression cloning and characterization of a novel adipocyte long chain fatty acid transport protein. Cell 79: 427–436, 1994.[CrossRef][Web of Science][Medline]
120. Schenk S, Horowitz JF. Coimmunoprecipitation of FAT/CD36 and CPT I in skeletal muscle increases proportionally with fat oxidation after endurance exercise training. Am J Physiol Endocrinol Metab 291: E254–E260, 2006.[Abstract/Free Full Text]
121. Schwieterman W, Sorrentino D, Potter BJ, Rand J, Kiang CL, Stump D, Berk PD. Uptake of oleate by isolated rat adipocytes is mediated by a 40-kDa plasma membrane fatty acid binding protein closely related to that in liver and gut. Proc Natl Acad Sci USA 85: 359–363, 1988.[Abstract/Free Full Text]
122. Sharma S, Adrogue JV, Golfman L, Uray I, Lemm J, Youker K, Noon GP, Frazier OH, Taegtmeyer H. Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. FASEB J 18: 1692–1700, 2004.[Abstract/Free Full Text]
123. Smith AC, Bruce CR, Dyck DJ. AMP kinase activation with AICAR further increases fatty acid oxidation and blunts triacylglycerol hydrolysis in contracting rat soleus muscle. J Physiol 565: 547–553, 2005.[Abstract/Free Full Text]
124. Smith AC, Bruce CR, Dyck DJ. AMP kinase activation with AICAR simultaneously increases fatty acid and glucose oxidation in resting rat soleus muscle. J Physiol 565: 537–546, 2005.[Abstract/Free Full Text]
125. Spitsberg VL, Matitashvili E, Gorewit RC. Association and coexpression of fatty-acid-binding protein and glycoprotein CD36 in the bovine mammary gland. Eur J Biochem 230: 872–878, 1995.[Web of Science][Medline]
126. Stahl A. A current review of fatty acid transport proteins (SLC27). Pflugers Arch 447: 722–727, 2003.[CrossRef][Web of Science][Medline]
127. Stahl A, Evans JG, Pattel S, Hirsch D, Lodish HF. Insulin causes fatty acid transport protein translocation and enhanced fatty acid uptake in adipocytes. Dev Cell 2: 477–488, 2002.[CrossRef][Web of Science][Medline]
128. Stahl A, Hirsch DJ, Gimeno RE, Punreddy S, Ge P, Watson N, Patel S, Kotler M, Raimondi A, Tartaglia LA, Lodish HF. Identification of the major intestinal fatty acid transport protein. Mol Cell 4: 299–308, 1999.[CrossRef][Web of Science][Medline]
129. Steinberg GR, Dyck DJ, Calles-Escandon J, Tandon NN, Luiken JJFP, Glatz JF, Bonen A. Chronic leptin administration decreases fatty acid uptake and fatty acid transporters in rat skeletal muscle. J Biol Chem 277: 8854–8860, 2002.[Abstract/Free Full Text]
130. Steinberg GR, Parolin ML, Heigenhauser GJF, Dyck DJ. Leptin increases fatty acid oxidation in lean but not obese human skeletal muscle: evidence of peripheral leptin resistance. Am J Physiol Endocrinol Metab 283: E187–E192, 2002.[Abstract/Free Full Text]
131. Stremmel W. Fatty acid uptake by isolated heart myocytes represents a carier-mediated transport process. J Clin Invest 81: 844–852, 1988.[Web of Science][Medline]
132. Stremmel W, Berk PD. Hepatocellular influx of [¹⁴C]oleate reflects membrane transport rather than intracellular metabolism or binding. Proc Natl Acad Sci USA 83: 3086–3090, 1986.[Abstract/Free Full Text]
133. Stremmel W, Strohmeyer G, Borchard F, Kochwa S, Berk PD. Isolation and partial characterization of a fatty acid binding protein in rat liver plasma membranes. Proc Natl Acad Sci USA 82: 4–8, 1985.[Abstract/Free Full Text]
134. Stump DD, Zhou SL, Berk PD. Comparison of plasma membrane FABP and mitochondrial isoform of aspartate aminotransferase from rat liver. Am J Physiol Gastrointest Liver Physiol 265: G894–G902, 1993.[Abstract/Free Full Text]
135. Summers SA, Garza LA, Zhou H, Birnbaum MJ. Regulation of insulin-stimulated glucose transporter GLUT4 translocation and Akt kinase activity by ceramide. Mol Cell Biol 18: 5457–5464, 1998.[Abstract/Free Full Text]
136. Tong F, Black PN, Coleman RA, DiRusso CC. Fatty acid transport by vectorial acylation in mammals: roles played by different isoforms of rat long-chain acyl-CoA synthetases. Arch Biochem Biophys 447: 46–52, 2006.[CrossRef][Web of Science][Medline]
137. Tunstall RJ, Mehan KA, Wadley GD, Collier GR, Bonen A, Hargreaves M, Cameron-Smith D. Exercise training increases lipid metabolism gene expression in human skeletal muscle. Am J Physiol Endocrinol Metab 283: E66–E72, 2002.[Abstract/Free Full Text]
138. Turcotte LP, Raney MA, Todd MK. ERK1/2 inhibition prevents contraction-induced increase in plasma membrane FAT/CD36 content and FA uptake in rodent muscle. Acta Physiol Scand 184: 131–139, 2005.[CrossRef][Web of Science][Medline]
139. Turcotte LP, Swenberger JR, Tucker MZ, Trump G, Yee AJ, Luiken JJFP, Bonen A. Muscle palmitate transport and binding are saturable and inhibited by antibodies to FABPpm. Mol Cell Biochem 210: 53–63, 2000.[CrossRef][Web of Science][Medline]
140. Turcotte LP, Swenberger JR, Tucker MZ, Yee AJ. Training-induced elevation in FABPpm is associated with increased palmitate use in contracting muscle. J Appl Physiol 87: 285–293, 1999.[Abstract/Free Full Text]
141. van der Vusse GJ, Roemen THM. Gradient of fatty acids from blood plasma to skeletal muscle in dogs. J Appl Physiol 78: 1839–1843, 1995.[Abstract/Free Full Text]
142. Watkins PA, Lu JF, Steinberg SJ, Gould SJ, Smith KD, Braiterman LT. Disruption of the Saccharomyces cerevisiae FAT1 gene decreases very long-chain fatty acyl-CoA synthetase activity and elevates intracellular very long-chain fatty acid concentrations. J Biol Chem 273: 18210–18219, 1998.[Abstract/Free Full Text]
143. Wu Q, Ortegon AM, Tsang B, Doege H, Feingold KR, Stahl A. FATP1 is an insulin-sensitive fatty acid transporter involved in diet-induced obesity. Mol Cell Biol 26: 3455–3467, 2006.[Abstract/Free Full Text]
144. Yu C, Chen Y, Cline GW, Zhang D, Zong H, Wang Y, Bergeron R, Kim JK, Cushman SW, Cooney GW, Atcheson B, White MF, Kraegen EW, Shulman GI. Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J Biol Chem 277: 50230–50236, 2002.[Abstract/Free Full Text]
145. Zou Z, Tong F, Faergeman NJ, Borsting C, Black PN, DiRusso CC. Vectorial acylation in Saccharomyces cerevisiae. Fat1p and fatty acyl-CoA synthetase are interacting components of a fatty acid import complex. J Biol Chem 278: 16414–16422, 2003.[Abstract/Free Full Text]

This article has been cited by other articles:

				J. F. C. Glatz, J. J. F. P. Luiken, and A. Bonen Membrane Fatty Acid Transporters as Regulators of Lipid Metabolism: Implications for Metabolic Disease Physiol Rev, January 1, 2010; 90(1): 367 - 417. [Abstract] [Full Text] [PDF]

				L. Q. Jiang, P. M. Garcia-Roves, T. de Castro Barbosa, and J. R. Zierath Constitutively active calcineurin in skeletal muscle increases endurance performance and mitochondrial respiratory capacity Am J Physiol Endocrinol Metab, January 1, 2010; 298(1): E8 - E16. [Abstract] [Full Text] [PDF]

				G. P. Holloway, S. S. Jain, V. Bezaire, X. X. Han, J. F. C. Glatz, J. J. F. P. Luiken, M.-E. Harper, and A. Bonen FAT/CD36-null mice reveal that mitochondrial FAT/CD36 is required to upregulate mitochondrial fatty acid oxidation in contracting muscle Am J Physiol Regulatory Integrative Comp Physiol, October 1, 2009; 297(4): R960 - R967. [Abstract] [Full Text] [PDF]

				G. R. Steinberg and B. E. Kemp AMPK in Health and Disease Physiol Rev, July 1, 2009; 89(3): 1025 - 1078. [Abstract] [Full Text] [PDF]

				J. G. Nickerson, H. Alkhateeb, C. R. Benton, J. Lally, J. Nickerson, X.-X. Han, M. H. Wilson, S. S. Jain, L. A. Snook, J. F. C. Glatz, et al. Greater Transport Efficiencies of the Membrane Fatty Acid Transporters FAT/CD36 and FATP4 Compared with FABPpm and FATP1 and Differential Effects on Fatty Acid Esterification and Oxidation in Rat Skeletal Muscle J. Biol. Chem., June 12, 2009; 284(24): 16522 - 16530. [Abstract] [Full Text] [PDF]

				J. S. Davies, P. Kotokorpi, S. R. Eccles, S. K. Barnes, P. F. Tokarczuk, S. K. Allen, H. S. Whitworth, I. A. Guschina, B. A. J. Evans, A. Mode, et al. Ghrelin Induces Abdominal Obesity Via GHS-R-Dependent Lipid Retention Mol. Endocrinol., June 1, 2009; 23(6): 914 - 924. [Abstract] [Full Text] [PDF]

				K. De Bock, W. Derave, B. O. Eijnde, M. K. Hesselink, E. Koninckx, A. J. Rose, P. Schrauwen, A. Bonen, E. A. Richter, and P. Hespel Effect of training in the fasted state on metabolic responses during exercise with carbohydrate intake J Appl Physiol, April 1, 2008; 104(4): 1045 - 1055. [Abstract] [Full Text] [PDF]

				CORRIGENDA Physiology, August 1, 2007; 22(4): 295 - 295. [Full Text] [PDF]

				A. Bonen, X.-X. Han, D. D. J. Habets, M. Febbraio, J. F. C. Glatz, and J. J. F. P. Luiken A null mutation in skeletal muscle FAT/CD36 reveals its essential role in insulin- and AICAR-stimulated fatty acid metabolism Am J Physiol Endocrinol Metab, June 1, 2007; 292(6): E1740 - E1749. [Abstract] [Full Text] [PDF]

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (54) Citing Articles via Google Scholar Google Scholar Articles by Bonen, A. Articles by Glatz, J. F. C. Search for Related Content PubMed PubMed Citation Articles by Bonen, A. Articles by Glatz, J. F. C.